Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $521,000.

  • Insight Molecular Diagnostics' Share-based Compensation rose 15.78% to $521,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 14.90%. This contributed to the annual value of $1.8 million for FY2024, which is 36.49% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Share-based Compensation of $521,000 as of Q3 2025, which was up 3.37% from $504,000 recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Share-based Compensation ranged from a high of $3.2 million in Q3 2022 and a low of $386,000 during Q2 2024.
  • For the 3-year period, Insight Molecular Diagnostics' Share-based Compensation averaged around $546,455, with its median value being $499,000 (2024).
  • In the last 5 years, Insight Molecular Diagnostics' Share-based Compensation soared by 73.10% in 2021 and then crashed by 81.52% in 2023.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Share-based Compensation stood at $1.7 million in 2021, then spiked by 53.61% to $2.6 million in 2022, then plummeted by 81.52% to $484,000 in 2023, then rose by 3.10% to $499,000 in 2024, then rose by 15.78% to $521,000 in 2025.
  • Its Share-based Compensation stands at $521,000 for Q3 2025, versus $504,000 for Q2 2025 and $473,000 for Q1 2025.